Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002159 | A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis | PHASE3 | COMPLETED | 60 | — | — | - | - | Jun 24, 2005 | 9 | United States |
| Name | Type | Description |
|---|---|---|
| Itraconazole | DRUG | - |
| Amphotericin B | DRUG | - |
Inclusion Criteria Patients must have: * HIV positive or negative status. * Blastomycosis or histoplasmosis. * Life expectancy of at least 1 week. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Liver disease. * Self-limiting fungal ...